Marshall Wace, LLP Ironwood Pharmaceuticals Inc Transaction History

Marshall Wace, LLP

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$5.58 - $8.61 $1.98 Million - $3.06 Million	-355,282 Reduced 62.06%	217,218 $1.42 Million
Q1 2024 May 15, 2024	BUY	$8.32 - $15.45 $2.37 Million - $4.4 Million	284,680 Added 98.91%	572,500 $4.99 Million
Q4 2023 Feb 14, 2024	BUY	$8.79 - $11.51 $1.23 Million - $1.61 Million	140,075 Added 94.81%	287,820 $3.29 Million
Q3 2023 Nov 14, 2023	BUY	$8.25 - $11.35 $1.22 Million - $1.68 Million	147,745 New	147,745 $1.42 Million
Q2 2021 Aug 13, 2021	BUY	$10.16 - $13.11 $4.12 Million - $5.32 Million	405,520 Added 3037.6%	418,870 $5.39 Million
Q1 2021 May 17, 2021	BUY	$9.04 - $11.86 $120,683 - $158,331	13,350 New	13,350 $149,000
Q4 2020 Feb 16, 2021	SELL	$9.05 - $12.2 $1.58 Million - $2.12 Million	-174,084 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$8.99 - $10.74 $552,345 - $659,865	61,440 Added 54.54%	174,084 $1.57 Million
Q2 2020 Aug 13, 2020	SELL	$9.14 - $11.97 $508,659 - $666,154	-55,652 Reduced 33.07%	112,644 $1.16 Million
Q1 2020 May 15, 2020	SELL	$8.58 - $14.01 $7.86 Million - $12.8 Million	-915,880 Reduced 84.48%	168,296 $1.7 Million
Q4 2019 Feb 14, 2020	SELL	$8.22 - $14.0 $154,988 - $263,970	-18,855 Reduced 1.71%	1,084,176 $14.4 Million
Q3 2019 Nov 14, 2019	BUY	$8.59 - $10.96 $8.8 Million - $11.2 Million	1,024,762 Added 1309.28%	1,103,031 $9.48 Million
Q2 2019 Aug 14, 2019	SELL	$9.8 - $12.89 $445,713 - $586,250	-45,481 Reduced 36.75%	78,269 $856,000
Q1 2019 May 14, 2019	BUY	$8.27 - $12.73 $1.02 Million - $1.58 Million	123,750 New	123,750 $1.67 Million

238

162M

11.2M

9.1K

Ticker IRWD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 153,231,008
Market Cap $541M
Description
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.